Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

Host defense peptides like KPV are being explored for their potential in treating inflammatory bowel diseases, but specific evidence and outcomes are not provided in this review.

Summary and findings

This article reviews host defense peptides (HDPs) as potential candidates for treating inflammatory bowel diseases (IBDs). It highlights various HDPs, including KPV, and discusses their antimicrobial and immunomodulatory properties. No specific numeric findings or clinical outcomes are reported in the abstract.

Abstract

Inflammatory bowel diseases (IBDs) are chronic disorders affecting the gastrointestinal tract, causing severe inflammation and tissue damage. Current treatments often have adverse effects, underscoring the need for alternatives. This article is a short review of host defense peptides (HDPs), which have emerged as promising candidates for IBDs because of their antimicrobial and immunomodulatory properties. The HDPs cited include cathelicidins [e.g. LL-37-Tα1, lipid transfer protein (LTP), C-L, KR-12], defensins [e.g. human alpha defensin 5 (HD-5), human beta-defensin 2 (hBD2)], cecropins (e.g. CC34), microcins [e.g. microcin J25 (MccJ25)], brevinins (e.g. chensinin-1), proline-rich antimicrobial peptides (PrAMPs) (e.g. abaecin), type V peptides [e.g. vasopressin-neurophysin (VP-NP)], and alpha-melanocyte-stimulating hormone (α-MSH) (e.g. KPV). HDPs have immunoregulatory mechanisms, downregulating the nuclear factor kappa B (NF-κB) pathway, modulating cytokine release, and restoring homeostasis. The data suggest that HDPs have therapeutic potential for IBDs, offering a way to reduce side effects, and we focus on this issue here.

Key findings

• Not reported in abstract.

Limitations

• Not reported in abstract.

Elsewhere in the KPV corpus